The Food and Drug Administration (FDA) approves GlaxoSmithKline's asthma medication for twice-a-year use.

GlaxoSmithKline announced on Tuesday that the US health regulatory agency has approved an additional medication for the treatment of severe asthma, paving the way for a treatment option with a lower dosing frequency to enter the market for patients.